| |  A study in Oncogene shows that PPP2R1A mutations increase sensitivity to ATR inhibitors in ARID1A-mutant ovarian clear cell carcinoma, suggesting a potential biomarker for improved treatment strategies. | |
|
| |  Research on cancer metastasis uncovers genetic complexities, showing that copy-number alterations play a key role in tumor evolution and treatment resistance. | |
|
| |  Researchers have discovered that plant-derived phytochemicals and their gut microbiome metabolites control the effectiveness of PI3K inhibitors in cancer therapy. The study reveals that dietary components, especially soy compounds processed by gut bacteria, can alter drug metabolism and impact treatment outcomes. | |
|
| |  Post-chemotherapy exercise significantly boosts disease-free survival in colon cancer patients, underscoring the importance of structured physical activity. | |
|
| |  Patients with Stage II and III (early-stage) HER2+ breast cancer usually undergo pre-operative therapy with multi-agent chemotherapy in combination with anti-HER2 antibodies, followed by surgery. | |
|
| |  The SWOG S2302 Pragmatica-Lung trial, which broke new ground with its streamlined pragmatic design, unusually broad eligibility criteria, and reduced data collection, has quickly answered its primary question, finding that the investigational combination it tested did not significantly extend overall survival compared to standard of care treatments. | |
|
| |  Results from a phase 3 clinical trial published in the New England Journal of Medicine, today (June 2nd) show that patients with lung cancer who received an immunotherapy drug, nivolumab, along with standard chemotherapy before surgery had improved long term survival compared to those who received chemotherapy alone, at 5 years after completing treatment. | |
|
| |  Reducing the length of immunotherapy treatment for an advanced skin cancer did not significantly diminish disease control when compared to giving treatments over a longer period, according to breakthrough research led by the Universities of Sheffield and Leeds and Sheffield Teaching Hospitals NHS Foundation Trust. | |
|
| |  Tests in 1,225 patients with the most deadly form of skin cancer reveal for the first time a genetic trait among most of those who did not respond to the latest cancer treatments, known as immune checkpoint inhibitors. | |
|
| |  Recent advances in cancer research have underscored the critical role of myeloid cells in shaping tumor microenvironments (TME), influencing tumor progression, immune evasion, and therapeutic resistance. | |
